Shares of AstraZeneca Pharma India surged 2.36% to Rs 8,615 on Thursday after the company reported a strong set of numbers for the quarter ended June 30, 2025. The stock gained Rs 198.50 from its previous close of Rs 8,416.50, with an intraday high of Rs 8,979.50 and a low of Rs 8,331.50. The company’s market capitalization currently stands at Rs 21,683 crore.
In Q1 FY26, AstraZeneca Pharma reported revenue from operations of Rs 526.3 crore, marking a 35.8% year-on-year jump from Rs 387.5 crore in the same quarter last year. Total income increased to Rs 537.5 crore from Rs 395.8 crore in Q1 FY25. The company posted a net profit of Rs 55.8 crore, a sharp turnaround from a loss of Rs 11.7 crore in the year-ago period. Profit before tax came in at Rs 74.7 crore, compared to a loss of Rs 15.1 crore last year.
The improvement was driven by higher sales volumes and effective cost management, which supported EBITDA growth despite a rise in expenses to Rs 462.4 crore from Rs 353.4 crore last year. Purchases of stock-in-trade rose to Rs 417.5 crore from Rs 240.3 crore a year earlier, while inventory adjustments stood at negative Rs 131.6 crore.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.